Doctor issues serious warning over 'most powerful weight loss jab ever' that outperforms Mounjaro and WeGovy

Weight loss injections are more popular than ever but even as science advances, there's no guarantee that they come risk free.

Ever since celebrities started showing off their significant weight loss, GLP-1 medications such as Ozempic, Wegovy and Mounjaro have become commonplace across the world.

Although they were initially designed as treatments to Type 2 diabetes, they have since switched their focus to weight loss, with Wegovy even available on the NHS to those who meet strict restrictions.

A new weight loss jab known as Retatrutide is threatening to blow the others out of the water, as it promises to target three different hormone receptors which will suppress appetite and increase fat burning.

It's already been dubbed the 'Godzilla of weight loss', since the more typically known medications target just one hormone receptor, and as it enters phase three of clinical trials, it's probably only a matter of time until it enters the market.

However, a doctor on TikTok has now raised a serious warning about the drug as media coverage of the 'miracle' medication continues to grow.

Dr Chris Raynor said: "Retatrutide is still in clinical trials, meaning real world crash test results aren't in yet. Unlike established medications or surgeries, the downside can hit where you least expect - your overall durability and function.

"Here is a fact. More advanced doesn't always mean better. The extra receptors targeted by these new triple agonists add complexity and possible side effects. Start by challenging flashy marketing and influencer advice and stick to regulated channels."

The doctor certainly isn't wrong, as we should always stick to medical and expert advice rather than the opinions of those on social media, especially after several TikTok users were banned last year for illegally advertising the weight loss drugs.

There is a lot of hope for Retatrutide of course, and while there are many benefits to the other GLP-1 medications, they do come with side effects and you'd expect a stronger version of them to pose other potential problems.

Professor Ania Jastreboff, lead investigator on the trial at Yale School of Medicine, added: "Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their neurometabolic disease.

"It was impressive to see that every dose of retatrutide resulted in clinically meaningful weight reduction for nearly all participants, and people with severe obesity on the highest dose lost on average 30 percent of their body weight over two years.

"Importantly, treatment with retatrutide not only resulted in robust weight reduction, but also in clear improvements in assessed cardiometabolic health measures.

"For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory."

LADbible Group has contacted Wegovy and Mounjaro for comment.